Activating mutations of the CTNNB gene characterize a subgroup of HCA, which carries an increased risk of malignant transformation into HCC (so-called ß-catenin-activated HCA, B-HCA) [1, 5–7]. The gene discussed is CTNNB1; the disease is hepatocellular adenoma.